ArticleTherapeutic advances in medical oncology2010
Practical considerations in ovarian cancer chemotherapy.
Article in Therapeutic advances in medical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials.Cancer biology & therapy · 2014Pooled it
- Tertiary cytoreduction for recurrence of ovarian CANCER patients after intraperitoneal chemotherapy.Frontiers in medicine · 2025Article
- Article
- Exosomes in diagnostic and therapeutic applications of ovarian cancer.Journal of ovarian research · 2024Review
- Pt(II)-PLGA Hybrid in a pH-Responsive Nanoparticle System Targeting Ovarian Cancer.Pharmaceutics · 2023Article
- Establishment of an optimized guinea pig model of cisplatin-induced ototoxicity.Frontiers in veterinary science · 2023Article
- Spontaneous Transformation of a p53 and Rb-Defective Human Fallopian Tube Epithelial Cell Line after Long Passage with Features of High-Grade Serous Carcinoma.International journal of molecular sciences · 2022Article
- Tuning the Biological Activity of Camphorimine Complexes through Metal Selection.Antibiotics (Basel, Switzerland) · 2022Article
- Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting.Medicina (Kaunas, Lithuania) · 2022Review
- Incidence, Mortality and Survival Analysis of Epithelial Ovarian Cancer in Brunei Darussalam.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients.Gynecologic oncology · 2022Article
- Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers.Cancers · 2021Review
- Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers.Proteomes · 2021Review
- Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma.OncoTargets and therapy · 2021Article
- Article
- Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.Advanced therapeutics · 2020Article
- Modeling of Chemoperfusion vs. Intravenous Administration of Cisplatin in Wistar Rats: Adsorption and Tissue Distribution.Molecules (Basel, Switzerland) · 2020Article
- Immobilization rapidly selects for chemoresistant ovarian cancer cells with enhanced ability to enter dormancy.Biotechnology and bioengineering · 2020Article
- Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer.Cancers · 2020Article
- Efficacy of Combination Therapy with Linalool and Doxorubicin Encapsulated by Liposomes as a Two-in-One Hybrid Carrier System for Epithelial Ovarian Carcinoma.International journal of nanomedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian cancer remains the most lethal gynecologic malignancy despite advances in treatment. The standard management generally involves a combination of surgical tumor debulking and chemotherapy. Over the decades, chemotherapy for ovarian cancer has evolved and currently involves a combination of intravenous platinum and taxane chemotherapy. Over the past decade, three randomized phase III trials have been reported, and all have demonstrated a significant survival advantage for intraperitoneal compared with intravenous chemotherapy. However, there are potential barriers and controversies related to the administration of intraperitoneal chemotherapy in ovarian cancer patients. In this review, we discuss the evolution and current management considerations of chemotherapy for the treatment of epithelial ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.